Clinical study of enzyme replacement therapy with idursulfase;Experiencia clínica del tratamiento de sustitución enzimática con idursulfasa

Revista de Neurologia

Volumn 44, Issue SUPPL. 1, 2007, Pages

  Gutiérrez Solana, Luis González ^a  

^a HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

Author keywords

Enzyme replacement therapy; Hunter syndrome; Iduronate 2 sulfatase; Idursulfase; Lysosomal diseases; Mucopolysaccharidosis II

Indexed keywords

GLYCOSAMINOGLYCAN; IDURONATE 2 SULFATASE; IMMUNOGLOBULIN G ANTIBODY; PLACEBO;

ABDOMINAL PAIN; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIBODY DETECTION; ANXIETY; ARTHRALGIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYANOSIS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ECZEMA; ENZYME REPLACEMENT; ERYTHEMA; FACE EDEMA; FATIGUE; FORCED EXPIRATORY VOLUME; HEADACHE; HEART ARRHYTHMIA; HUMAN; HUNTER SYNDROME; HYPERTENSION; HYPOTENSION; KNOCKOUT MOUSE; LACTATE DEHYDROGENASE BLOOD LEVEL; LYSOSOME STORAGE DISEASE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; NAUSEA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; TACHYCARDIA; THORAX PAIN; TISSUE; TREMOR; URINE; URTICARIA; VOMITING; WALKING;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; HUMANS; IDURONATE SULFATASE; MUCOPOLYSACCHARIDOSIS II;

EID: 37249033169     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Wraith JE. Advances in the treatment of lysosomal storage disease. Dev Med Child Neurol 2001; 43: 639-46.
2. Pastores GM, Barnett NL. Current and emerging therapies for the lysosomal storage disorders. Expert Opin Emerging Drugs 2005; 10: 891-902.
3. Gutiérrez-Solana LG. Avances en el tratamiento de las enfermedades lisosomales en la infancia. Rev Neurol 2006; 43 (Supl 1): S137-44.
4. Hobbs JR, Hugh-Jones K, Barrett AJ, Byrom N, Chambers D, Henry K, et al. Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet 1981; 2: 709-12.
5. Peters C, Steward CG, National Marrow Donor Program, International Bone Marrow Transplant Registry, Working Party on Inborn Errors, European Bone Marrow Transplant Group. Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone Marrow Transplant 2003; 31: 229-39.
6. Desnick RJ. Enzyme replacement and enhancement therapies for lysosomal diseases. J Inherit Metab Dis 2004; 27: 385-410.
7. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited enzyme deficiency macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991; 324: 1464-70.
8. Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, et al. Effectiveness of enzyme replacement therapy in 1,028 patients with type 1 Gaucher disease after 2-5 years of treatment: a report from the Gaucher Registry. Am J Med 2002; 113: 112-9.
9. Baldellou A, Andria G, Campbell PE, Charrow J, Cohen IJ, Grabowski GA, et al. Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur J Pediatr 2004; 163: 67-75.
10. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 2001; 345: 9-16.
11. Schiffmann R, Kopp JB, Austin HA III, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001; 285: 2743-9.
12. Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001; 344: 182-8.
13. Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human ?-L-iduronidase (laronidase). J Pediatr 2004; 144: 581-8.
14. Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, Van der Ploeg AT. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 2000; 356: 397-8.
15. Kishnani PS, Nicolino M, Voit T, Rogers RC, Tsai AC, Waterson J, et al. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 2006; 149: 89-97.
16. Harmatz P, Giugliani R, Schwartz I, Guffon N, Teles EL, Miranda MC, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open label extension study. J Pediatr 2006; 148: 533-9.
17. Hunley TE, Corzo D, Dudek M, Kishnani P, Amalfitano A, Chen YT, et al. Nephrotic syndrome complicating ?-glucosidase replacement therapy for Pompe disease. Pediatrics 2004; 114: e532-5.
18. Rosenberg M, Kingma W, Fitzpatrick MA, Richards SM. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood 1999; 93: 2081-8.
19. Kakavanos R, Turner CT, Hopwood JJ, Kakkis ED, Brooks DA. Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I. Lancet 2003; 361: 1608-13.
20. McKinnis EJ, Sulzbacher S, Rutledge JC, Sanders J, Scott CR. Bone marrow transplantation in Hunter syndrome. J Pediatr 1996; 129: 145-8.
21. Vellodi A, Young E, Cooper A, Lidchi V, Winchester B, Wraith JE. Long-term follow-up following bone marrow transplantation for Hunter disease. J Inherit Metab Dis 1999; 22: 638-48.
22. Muenzer J, Lamsa JC, García A, Dacosta J, García J, Treco DA. Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report. Acta Paediatr 2002; 439: S98-9.
23. Muenzer J, Towle D, Calikoglu M, McCandless S. The 12-months experience of enzyme replacement for mucopolysaccharidosis II (Hunter syndrome). J Inherit Metab Dis 2003; 26 (Suppl 2): S144.
24. Muenzer J, Calikoglu M, Conway AM, Kimura A. The long-term experience of enzyme replacement for Hunter syndrome (MPS II). J Inherit Metab Dis 2005; 28 (Suppl 1): S188.
25. Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006; 8: 465-73.
26. Del Toro-Riera M. Seguimiento de pacientes con síndrome de Hunter: el registro HOS (Hunter Outcome Survey). Rev Neurol 2007; 44 (Supl 1): S13-7.